Alpha Tau Medical's book value per share for the quarter that ended in Mar. 2026 was $0.77.
During the past 12 months, Alpha Tau Medical's average Book Value Per Share Growth Rate was -1.60% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -16.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Alpha Tau Medical was -16.90% per year. The lowest was -16.90% per year. And the median was -16.90% per year.
Alpha Tau Medical's current price is $13.575. Its book value per share for the quarter that ended in Mar. 2026 was $0.77. Hence, today's PB Ratio of Alpha Tau Medical is 17.65.
During the past 7 years, the highest P/B Ratio of Alpha Tau Medical was 18.16. The lowest was 0.00. And the median was 0.00.
Alpha Tau Medical (NAS:DRTS) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Alpha Tau Medical Book Value per Share Related Terms
Alpha Tau Medical Book Value per Share Historical Data
* Premium members only.
The historical data trend for Alpha Tau Medical's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DRTS vs ORIC, OLMA, KURA: Book Value per Share Comparison
For the Biotechnology subindustry, Alpha Tau Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alpha Tau Medical PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alpha Tau Medical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Alpha Tau Medical's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alpha Tau Medical (DRTS) has a Book Value per Share of $0.77 as of Mar. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Alpha Tau Medical and its competitors.
Is Alpha Tau Medical's Book Value per Share too high?
Alpha Tau Medical's current Book Value per Share is $0.77. Overall, Alpha Tau Medical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Alpha Tau Medical's Book Value per Share compare to ORIC and OLMA?
Alpha Tau Medical's Book Value per Share of $0.77 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Biotechnology company?
A good Book Value per Share depends on the Biotechnology industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Alpha Tau Medical and its competitors. Alpha Tau Medical's current Book Value per Share is $0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alpha Tau Medical stock overvalued right now?
Alpha Tau Medical (DRTS) has a current Book Value per Share of $0.77. The current Book Value per Share is $0.77. Alpha Tau Medical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Alpha Tau Medical (DRTS), the current Book Value per Share is $0.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
28GF Score
Get the complete analysis for DRTS
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DRTS has been successfully added to your 
